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The Road Connecting Obesity
and Coronary Vasomotor Function
Straight Line or U-Turn?*
Robert J. Gropler, MD
St. Louis, MissouriF
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eObesity as reached epidemic proportions globally,
with approximately one-half billion people (12% of
the world’s population) considered obese (1). In the
United States alone, the prevalence of obesity has
increased by 50% in the past 30 years to where
now 70% of all adults are classified as either
overweight or obese (2). More sobering is that
30% of all children between 2 and 19 years of age
fall into these 2 categories (3). Obesity is typically
defined as a body mass index (BMI) of 30 kg/m2.
See page 805
The presence of obesity has a significant unfavor-
able impact on cardiovascular (CV) health through
the complex interplay of systemic and direct cardiac
effects (Table 1). For example, the synergistic effects
of an increase in total blood volume and the
presence of hypertension and increased insulin re-
sistance (e.g., diabetes mellitus) stimulate left ven-
tricular remodeling, resulting in significant left
ventricular systolic and diastolic dysfunction with
heart failure (with either reduced or preserved
ejection) being the outcome. Similarly, the conflu-
ence of key risk factors for coronary heart disease
(e.g., dyslipidemia, hypertension, and insulin-
resistant states) with an inflammatory and pro-
thrombotic environment appears to increase the
prevalence of this disease in obese individuals.
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the Division of Radiological Sciences, Mallinckrodt Institute of
Radiology, Washington University School of Medicine, St. Louis,m
Missouri. Supported in part by NIH grant P01-HL-13581 and
HHSN268201000046C to Dr. Gropler.inally, the amalgamation of these adverse cardiac
ffects results in an increased prevalence of atrial
nd ventricular arrhythmias. Consequently, obesity
as been implicated as one of the major risk factors
or heart failure, coronary heart disease, and sudden
ardiac death. However, unlike other conventional
isk factors such as hypertension and dyslipidemia
n which the relationship with CV events is con-
inuous or linear, evidence from clinical cohorts of
atients with established CV diseases indicates a
ore complex and even paradoxical relationship
etween obesity and CV disease. For example, the
resence of obesity has been associated with a more
avorable short- and long-term prognosis in pa-
ients with coronary heart disease and various forms
f heart failure (4). Furthermore, post-mortem
tudies suggest a reduced atherosclerotic burden in
ndividuals with obesity as well as morbid obesity
BMI 40 kg/m2) (5). This complex relationship
as been termed the obesity paradox. The reasons
esponsible for the dichotomous effects of obesity
n CV health are poorly understood. Clearly, the
ifficulty in separating out the adverse CV effects
rom obesity alone, from the contributions of its
ther systemic abnormalities, is 1 potential expla-
ation. Moreover, the presence of obesity may
itigate the cachexia associated with advanced
eart failure. That being said, other mechanisms
re likely to be operational, particularly those that
ontribute to the beneficial CV effects of obesity.
In this issue of iJACC, Quercioli et al. (6) attempt
o provide further insight into the potential mech-
nisms responsible for the complex relationship
etween obesity and CV health. They focused their
fforts on answering the question of whether abnor-
alities in coronary vasomotor function were more
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817pronounced in morbidly obese individuals com-
pared with obese individuals and, if so, could differ-
ences in the systemic levels of leptin, adiponectin,
endocannabinoids, and C-reactive protein be con-
tributory? Leptin and adiponectin are adipocyte-
derived hormones with divergent effects on vascular
morphology and function. Leptin possesses pro-
coagulant and antifibrinolytic properties and pro-
motes thrombus and atheroma formation, probably
through the leptin receptors by promoting vascular
inflammation, proliferation, and calcification and by
increasing oxidative stress. Thus, it appears to
impair vascular morphology and function. In con-
trast, adiponectin inhibits the expression of key
adhesion molecules (e.g., intercellular adhesion
molecule-1 and vascular cell adhesion molecule-1),
interferes with monocyte adherence to endothelial
cells and their subsequent migration to the suben-
dothelial space, and exhibits potent anti-inflammatory
effects by inhibiting the transformation of macro-
phages to foam cells and decreases their phagocytic
activity. Thus, it appears to enhance vascular mor-
phology and function. Consequently, the increases
in systemic leptin levels and decrease in adiponectin
levels in obesity are likely contributory to the observed
perturbations in vascular function. The endocannabi-
noids, such as anandamide and 2-arachidonoylglycerol,
are endogenous bioactive lipid mediators derived
from arachidonic acid. They are physiologically
synthesized and released on demand from a variety
of tissues such as brain, peripheral organs, and
adipose tissue. The endocannabinoids exert their
biological effects via interaction with the specific G
protein–coupled cannabinoid receptors types 1 and 2,
which appear to activate divergent functions (7). For
example, increases in adipocyte-derived endocannabi-
noids have been suggested to exert proatherosclerotic
effects by signaling via cannabinoid receptor type 1
and/or noncannabinoid receptors in the vascular wall
with resultant increases in oxidative stress, vascular
smooth muscle cell proliferation, and recruitment of
monocytes and neutrophils into the arterial wall.
Conversely, stimulation of the cannabinoid receptor
type 2 appears to mediate anti-inflammatory and
antiatherosclerotic effects. Thus, systemic endocan-
nabinoids levels may well contribute to obesity-related
abnormalities in vascular function.
The investigators studied 4 groups of subjects
stratified by BMI; a control group (BMI 20 to 24.9
kg/m2), overweight group (BMI 25 to 29.9 kg/m2),
an obese group (BMI 30 to 39.9 kg/m2), and a
morbidly obese group (BMI40 kg/m2). Coronary
asomotor function was determined by measuring oyocardial blood flow with 13N-ammonia positron
mission tomography/computed tomography at rest
nd in response to a cold-pressor test to measure
ndothelium-dependent vasodilation and to pharma-
ologically induced hyperemia. Results were compared
ith various anthropomorphic measurements and
lasma adipokine, endocannabinoid, and C-reactive
rotein levels.
Several interesting observations arose from this
tudy. First, there was a progressive decrease in
ndothelium-dependent vasodilation across the spec-
rum of individuals who were normal weight, over-
eight, and obese that did not continue in the pres-
nce of morbid obesity. Second, hyperemic blood flow
as reduced to a comparable level among all groups with
ncreases in body weight, suggesting a threshold effect
or the impairment. Third, increases in plasma levels
f anandamide and 2-arachidonoylglycerol were in-
ersely associated with an impairment of the myocar-
ial blood flow response to cold-pressor testing in
bese individuals, suggestive of adverse effects of
ndocannabinoids on the coronary endothelium, but
his association was not observed in individuals with
orbid obesity. Finally, elevations of leptin and high-
ensitivity C-reactive protein plasma levels were posi-
ively correlated with endothelium-related vasodila-
ion in morbidly obese individuals.
The results of this study provide further credence
hat BMI alone is an inadequate marker of obesity-
elated CV risk and the existence of a paradoxical
elationship between obesity and CV health and in
articular, sheds light on the impact of severity of
besity on coronary vasomotor function. The study
lso raises several intriguing questions. The findings
Table 1. Effects of Obesity on the Cardiovascular System
Systemic Car
Insulin resistance Altered cardiac geom
Glucose intolerance Left atrial enlargem
Metabolic syndrome LV concentric and e
Diabetes mellitus LV remodeling
Dyslipidemia LV dysfunction
Increases in total and LDL cholesterol
and triglycerides
Diastolic
Systolic
Decrease in HDL cholesterol
Hypertension Endothelial dysfunctio
Increased inﬂammation Coronary artery disea
Prothrombotic state Heart failure
Arrhythmias
Atrial ﬁbrillation
Ventricular tachycardi
HDL  high-density lipoprotein; LDL  low-density lipoprotein; LV  left ventdiac
etry
ent
ccentric hypertrophy
n
se
a and ﬁbrillationf relatively preserved vasomotor function and a
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818positive association with leptin and high-sensitivity
C-reactive protein levels in individuals with more
severe obesity are consistent with previous reports
(8). It is well-known that adipocytes are a source of
not only inflammatory mediators such as adipo-
kines, but also endothelial progenitor cells. Al-
though controversial, these cells may provide a
protective and reparative function on the endothe-
lium. Thus, is it possible that, at a critical fat mass,
enough progenitor cells are produced and mobi-
lized, perhaps via stimulation by the inflammatory
microenvironment, to have a beneficial effect on
endothelial function? Are the results of the study
applicable to men and women, and, if so, what is
the effect of menopausal status? The results of the
current study would suggest that men might be
more susceptible than women to obesity-related
abnormalities in coronary vasomotor function, but
larger studies are needed to confirm this observa-
tion. Finally, what are the implications of the study
on the use of weight loss in obese cardiac patients?
Weight loss is routinely prescribed for obese cardiacand adolescents, 2007–2008. JAMA
2010;303:242–9.
4
5
6
tion. J Am Coll Ca
805–15.and decreasing CV risk. Indeed, recent data suggest
that bariatric surgery in morbidly obese patients can
greatly reduce various obesity-related CV risk fac-
tors with subsequent salutary effects on long-term
CV outcome (9). However, based on the results of
the current study, is there an early time window
during weight loss when CV risk may actually
increase, and, if so, is more intensive monitoring
needed during this time? Moreover, given differ-
ent metabolic, proinflammatory and potentially
progenitor cell profiles of different types of adi-
pose tissue (e.g., subcutaneous vs. visceral fat),
should weight reduction be targeted to specific fat
depots?
The performance of more high-quality studies
such as the one conducted by Quercioli et al. (6)
should help to further unravel the complex relation-
ship between obesity and CV disease.
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